Anlon Healthcare Limited has released its comprehensive investor presentation for Q3 and nine months of FY26, following the scheduled earnings conference call on February 19, 2026. The pharmaceutical company shared detailed financial results and strategic insights for the period ended December 31, 2025, demonstrating robust growth across key performance metrics.

Q3 FY26 Financial Performance

The company delivered exceptional financial results in Q3 FY26, showcasing significant year-over-year improvements across all major parameters.

Nine Months FY26 Consolidated Results

The nine-month performance further reinforced the company's strong growth trajectory with substantial improvements in profitability metrics.

Conference Call and Investor Presentation Details

The earnings conference call was conducted on February 19, 2026, at 4:00 PM IST via Zoom Webinar, led by Mr. Punit Rasadia, Chairman & Managing Director. The comprehensive investor presentation has been uploaded on the company's website and can be accessed at https://www.anlon.in/reports.php?subid=15&name=Investor-Meet .

Business Highlights and Growth Metrics

Anlon Healthcare showcased impressive operational achievements in its investor presentation, highlighting its expanding global footprint and diversified product portfolio.

Strategic Growth Outlook

The company outlined ambitious expansion plans with combined installed capacity expected to reach 1,400-1,600 MTPA post expansion. Management targets 3-5 DMF filings in FY 2026-27 to strengthen regulated-market penetration and anticipates launching 7 new APIs across additional therapeutic categories. The company is positioned to deliver approximately 30% revenue CAGR over the next three years, supported by acquisitions and new product launches, while maintaining sustainable EBITDA margins of 25-30%.

Anlon Healthcare Limited has submitted its quarterly monitoring agency report for Q3FY26 to stock exchanges, demonstrating continued progress in IPO fund utilization under regulatory oversight. The pharmaceutical company, which raised ₹12,103.00 lakh through its public issue, reported utilizing ₹9,579.04 lakh of the proceeds as of December 31, 2025.

Regulatory Compliance and Monitoring Framework

Pursuant to Regulation 30 and 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the company submitted the monitoring agency report issued by CRISIL Ratings Limited on February 10, 2026. The report covers the quarter and nine months ended December 31, 2025.

IPO Fund Utilization Progress

The monitoring report reveals systematic deployment of IPO proceeds across stated objectives, with no deviations from the original prospectus disclosures. The company has maintained transparency in fund utilization while progressing on expansion plans.

Object-wise Fund Deployment

The company has made significant progress across all stated objectives, with complete utilization in debt repayment and working capital requirements.

The company utilized ₹1,333.59 lakh during Q3FY26, with ₹853.59 lakh deployed for general corporate purposes toward meeting expenses incurred in ordinary business operations.

Unutilized Funds Management

The remaining ₹2,523.96 lakh has been strategically deployed in fixed deposits and current accounts to ensure optimal returns while maintaining liquidity for ongoing projects.

Compliance and Governance Highlights

The monitoring agency confirmed no deviations from stated objectives and no material changes in financing arrangements. The company has obtained Consent to Establishment (CTE) approval for its expansion project, with other statutory approvals in progress. CRISIL Ratings noted that vendor arrangements have been modified compared to prospectus disclosures, but these changes align with the flexibility provisions outlined in the original offer document.

The Board of Directors ratified and approved the utilization of proceeds under General Corporate Purposes through a resolution dated February 09, 2026, ensuring proper governance oversight of fund deployment.